menù
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Maccauro Marco
Main Facility: Nuclear Medicine
Drug: Iodine-124 (for PET imaging and dosimetry) Iodine-131 (for targeted)
Phase: Phase III clinical trials
Principal Investigator: Dott. Del Vecchio Michele
Main Facility: Medical Oncology 1 – Medical Oncology Unit: Melanoma
Drug: Tebentafusp (IMCgp100)
Phase: Non-pharmacological interventional studies
Principal Investigator: Dr. Montroni Isacco
Main Facility: Colon and Rectal Surgery Unit
Principal Investigator: Dr. Procopio Giuseppe
Main Facility: Genitourinary Medical Oncology
Drug: Pembrolizumab + Enfortumab
Principal Investigator: Dr. Lanocita Rodolfo
Main Facility: Diagnostic and Interventional Radiology Unit
Drug: Thermal ablation devices (radiofrequency or microwave ablation probes)
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Breast Medical Oncology
Drug: RO7771950
Main Facility: Medical Oncology 1
Drug: RO7771950 (ZN-A-1041)
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Verzoni Elena
Drug: tulmimetostat e jsb462
Phase: Phase IV clinical trials
Principal Investigator: Dr. Stacchiotti Silvia
Main Facility: Medical Oncology 2
Drug: Nirogacestat
Principal Investigator: Dott. Alfieri Salvatore
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: Avelumab, Cetuximab
Principal Investigator: Dott.ssa Angi Martina
Main Facility: Oncologic General Surgery 4 - Melanoma and Eye Tumors
Drug: Darovasertib
Principal Investigator: Dr. Prelaj Arsela
Main Facility: Thoracic Oncology Unit
Drug: MK2870 (sacituzumab tirumotecan) Docetaxel Pemetrexed
Principal Investigator: Dr. Lo Russo Giuseppe
Drug: MK-2870 (sacituzumab tirumotecan) Pembrolizumab
Drug: Ivonescimab (SMT112)
Drug: Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
Principal Investigator: Dr. Gronchi Alessandro
Main Facility: General Surgery 7 – Sarcomas
Drug: For high-risk Dedifferentiated Liposarcoma (DDLPS): Doxorubicin + Ifosfamide. For Leiomyosarcoma (LMS): Doxorubicin + Dacarbazine.
Principal Investigator: Dr. Proto Claudia
Drug: BMS-986504
Drug: Saruparib (AZD5305)
Phase: Phase II clinical trials
Drug: Giredestrant, Inavolisib, Abemaciclib
Drug: Giredestrant (GDC-9545); Abemaciclib (LY2835219); Inavolisib (GDC-0077)
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe